Standing Order
Tempus AI, Inc.

Dashboard

Tempus AI, Inc.

TEMNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$7.5B
Price$42.6952w $42.37 – $103.25
Conviction4/ 5
Revenue (TTM)$1.4B
Revenue growth YoY+69.8%
P/E (trailing)—
Gross margin69.6%
Operating margin-18.1%
Net margin-22.2%
52w price change-32.7%
Next earningsJul 30, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Jul 20
    OtherSEC

    8-K filing (items 7.01, 9.01) disclosing Reg FD information.

  • Jul 20
    DealSEC

    8-K filed with items 1.01 and 9.01 disclosing entry into material definitive agreement.

  • Jul 20
    M&ASEC

    SEC Form 425 filing on business combination communications.

  • Jul 20
    M&ASEC

    SEC Form 425 filing for business combination communications.

  • Jul 20
    M&ASEC

    SEC Form 425 filing for business combination communications.

  • Jul 20
    M&ASEC

    Tempus AI filed SEC Form 425 regarding a business combination.

  • Jul 20
    M&ASEC

    SEC Form 425 filing for business combination.

  • Jul 10
    Ownership changeSEC

    Form 4 insider transaction filed

  • Jul 8
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jul 1
    Ownership changeSEC

    Form 4 insider transaction filing on 2026-07-01.

  • Jun 29
    Ownership changeSEC

    SEC Form 4 filing reporting change in insider beneficial ownership.

  • Jun 29
    Ownership changeSEC

    Form 4 insider ownership filing on 2026-06-29.

  • Jun 4
    Trial initiationClinicalTrials.gov

    Phase 1 trial (NCT07250646) of Rebecsinib recruiting for relapsed/refractory AML or high-risk myelofibrosis; sponsor Aspera Biomedicines

  • Jun 3
    Ownership changeSEC

    Form 4 insider ownership change filing.

  • Jun 2
    Trial initiationClinicalTrials.gov

    A2 Biotherapeutics trial NCT04981119 (solid tumor HLA LOH, CAR T apheresis) status updated to recruiting.

  • May 29
    OtherSEC

    Form 4 filing on change in beneficial ownership by insider

  • May 26
    OtherSEC

    SEC Form 4 filing on beneficial ownership change

  • May 26
    OtherSEC

    Form 4 filing reporting change in beneficial ownership.

  • May 26
    OtherSEC

    Form 4 insider transaction filing reported for Tempus AI.

  • May 26
    OtherSEC

    SEC Form 4 insider ownership filing.

Not financial advice — research and opinion only. Disclosures